Drugmaker AbbVie Inc raised its full-year profit forecast on Friday, bolstered by signs of recovery in demand for its Botox injection on easing COVID-19 restrictions and strong growth for its latest drugs, sending its shares up 6%.
Moderna Inc on Thursday said it is on track to report early data from a late-stage trial of its experimental COVID-19 vaccine next month, offering the clearest timeline yet for when the world will know whether it is effective.
Oct 28 The U.S. government has agreed to pay
$375 million to Eli Lilly and Co for 300,000 doses of
its experimental COVID-19 antibody treatment, a drug similar to
a treatment that U.S. President Donald Trump received.
Novavax Inc on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.
Drugmaker Pfizer Inc said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany's BioNTech SE , and provided a timeline that makes its release unlikely ahead of the Nov. 3 U.S. presidential election.Pfizer said there had not yet been enough infections in the 44,000-volunteer trial to trigger an analysis of whether or not the vaccine works. An independent panel will conduct the first analysis when it reaches 32 infections.
Biogen Inc said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.
Oct 21 Biogen Inc said on Wednesday it
was diverting part of its budget and resources for blockbuster
multiple sclerosis drug Tecfidera towards a potential launch of
its Alzheimer's disease drug, aducanumab.
Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year. | Video